Upjohn/Mylan: Will "Potential Moderate Growth" Lure Investors?
Executive Summary
The combined company will have pro forma 2020 revenues of $19bn to $20bn, generate $1bn in synergies by 2023 and be led by Upjohn CEO Michael Goettler. Mylan's longtime CEO Heather Bresch will depart.
You may also be interested in...
Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.